Results 1 to 10 of about 4,153 (212)

Finerenone in IgA nephropathy: real-world 12-month propensity-matched cohort demonstrating proteinuria reduction, eGFR preservation, and safety profile [PDF]

Renal Failure
Objective To evaluate the efficacy and safety of finerenone in patients with IgA nephropathy (IgAN).Methods This retrospective study included 105 patients with IgAN (35 in the finerenone group, 70 in the control group) from January 2022 to February 2025.
Wei Zhang, Jing-ting Yu, Bo Lin, Xiaogang Shen, Maosheng Chen, Yi-dong Zhou, Yu-jia Zhang, Cheng-cong Zhuo, Zhi-liang Jiang, Bin Zhu   +9 more
doaj   +2 more sources

Cardioprotective Effects of Finerenone Associated With the Suppression of Myocardial Sodium Accumulation in Aldosterone/Salt‐Loaded Rats [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Clinical trials have indicated that finerenone, a nonsteroidal mineralocorticoid receptor antagonist, elicits considerable cardiovascular protective benefits; however, its precise mechanism of action remains to be fully elucidated.
Asadur Rahman, Tatsuya Sawano, Kento Kitada, Nourin Jahan, Yoshihide Fujisawa, Keiko Yamakawa, Md Moshiur Rahman, Juanjuan Ye, Md Enayet Kabir, Kyuichi Kadota, Takeshi Imamura, Hiroyuki Ohsaki, Daisuke Yamazaki, Takashi Morikawa, Yoshio Konishi, Akira Nishiyama   +15 more
doaj   +2 more sources

Finerenone as an add-on treatment to conventional therapies for the patients with diabetic kidney disease [PDF]

BMC Nephrology
Background Finerenone has been shown to exert renoprotective effects in patients with diabetic kidney disease. However, the effects of finerenone on proteinuria and serum potassium levels in patients already receiving renin–angiotensin system inhibitors ...
Satoshi Kidoguchi, Sugano Naoki, Yohei Suehiro, Takashi Yokoo   +3 more
doaj   +2 more sources

Utilization and clinical characteristics of patients with type 2 diabetes and chronic kidney disease prescribed finerenone in the United States [PDF]

Journal of Clinical & Translational Endocrinology
Background: Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, improves renal and cardiovascular outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).
Csaba P. Kovesdy, Craig I. Coleman, Catherine B. Johannes, Anam M. Khan, Ryan Ziemiecki, J. Bradley Layton, David Vizcaya, Fangfang Liu, Nikolaus G. Oberprieler   +8 more
doaj   +2 more sources

A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD [PDF]

Kidney International Reports
Introduction: Finerenone demonstrated kidney and cardiovascular benefits in participants with chronic kidney disease (CKD) and type 2 diabetes (T2D) on optimized renin-angiotensin system (RAS) inhibition in FIDELITY, a pooled individual-level analysis of
Ajay K. Singh, Stefan D. Anker, Bertram Pitt, Peter Rossing, Luis M. Ruilope, Christiane Ahlers, Youssef M.K. Farag, Marc Lambelet, Meike D. Brinker, Katja Rohwedder, Gerasimos Filippatos   +10 more
doaj   +2 more sources

Finerenone in kidney transplantation: an underinvestigated agent: review of available evidence, existing gaps, and future directions [PDF]

Clinical Transplantation and Research
Emerging data on finerenone have drawn significant interest from nephrologists and cardiologists for its clinical potential in patient management. Its nonsteroidal structure, greater receptor selectivity, and reduced risk of hyperkalemia make it a ...
Muhammad Abdul Mabood Khalil, Nihal Mohammed Sadagah, Muhammad Shahab Uddin Khalil, Hideki Ishida, Jackson Tan, Salem H Al-Qurashi   +5 more
doaj   +2 more sources

Role of L‐type Ca2+‐channels in the vasorelaxing response to finerenone in arteries of human visceral adipose tissue [PDF]

Physiological Reports
Inadequate blood supply to the expanding adipose tissue (AT) is involved in the unhealthy AT remodeling and cardiometabolic consequences of obesity. Because of the pathophysiological role of upregulated mineralocorticoid receptor (MR) signaling in the ...
Francesca Schinzari, Alessandro De Stefano, Giuseppe Sica, Marco Mettimano, Carmine Cardillo, Manfredi Tesauro   +5 more
doaj   +2 more sources

Finerenone in mildly reduced or preserved ejection fraction and chronic kidney disease: a narrative review [PDF]

The Egyptian Heart Journal
Background In patients with type 2 diabetes and chronic kidney disease (CKD) heart failure with preserved ejection fraction is associated with considerable morbidity and it has fewer treatment options available. HFpEF, which is characterized by increased
Muhammad Shaheer Bin Faheem, Hafiza Qurat Ul Ain, Aatka Rauf, Qasra Faheem, Own E Mohammad Najmi   +4 more
doaj   +2 more sources

Targeting LTBP2 Reveals a Novel Anti-Cardiac Remodeling Mechanism of Finerenone Against Doxorubicin-Induced Cardiotoxicity [PDF]

Biomolecules
Despite the clinical efficacy of doxorubicin (DOX), effective strategies to prevent its cardiotoxicity are still lacking. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), has demonstrated cardioprotective properties; however, its ...
Heng Zhang, Nan Zhao, Saiyang Xie, Lanlan Li, Xiaofeng Zeng, Shasha Wang, Ling Yan, Bo Shen, Wei Deng   +8 more
doaj   +2 more sources

Effects of finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomised placebo-controlled mechanistic trial (FIVE-STAR) [PDF]

Cardiovascular Diabetology
Background The mechanisms underlying cardiorenal benefits of finerenone remain unclear. This mechanistic trial aimed to evaluate the effects of finerenone on vascular stiffness, as assessed using the cardio-ankle vascular index (CAVI), and cardiorenal ...
Atsushi Tanaka, Muthiah Vaduganathan, Takumi Imai, Yosuke Okada, Satomi Sonoda, Keiichi Torimoto, Satoru Suwa, Hiroki Teragawa, Motoaki Miyazono, Makoto Fukuda, Keisuke Yonezu, Naohiko Takahashi, Yuichi Yoshida, Kenichi Tanaka, Michio Shimabukuro, Yuki Hotta, Masao Moroi, Hiroki Niikura, Keisuke Kida, Kenichi Yokota, Daiju Fukuda, Kengo Tanabe, Yu Horiuchi, Shigeru Toyoda, Isao Taguchi, Hisako Yoshida, Toru Miyoshi, Masaomi Nangaku, Hirotaka Shibata, Koichi Node, on behalf of the FIVE-STAR Investigators   +30 more
doaj   +2 more sources